Technical Analysis for BNOEF - Bionomics Ltd

Grade Last Price % Change Price Change
grade D 0.0456 111.11% 0.0240
BNOEF closed up 111.11 percent on Friday, September 20, 2019, on 4 percent of normal volume.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Down Down Up
See historical BNOEF trend table...

Date Alert Name Type % Chg
Crossed Above 20 DMA Bullish 0.00%
Narrow Range Bar Range Contraction 0.00%
Wide Bands Range Expansion 0.00%
Gapped Up Strength 0.00%
Narrow Range Bar Range Contraction 111.11%
Wide Bands Range Expansion 111.11%
Down 3 Days in a Row Weakness 111.11%
Gapped Down Weakness 111.11%
Narrow Range Bar Range Contraction 14.57%
Wide Bands Range Expansion 14.57%

Older signals for BNOEF ...

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Bionomics Limited, a clinical-stage biopharmaceutical company, discovers and develops novel drug candidates for the treatment of central nervous system disorders and cancer in Australia, France, and the United States. It operates through Drug Discovery and Development, and Contract Services segments. The company's product pipeline includes BNC210, a negative allosteric modulator, which is in Phase II clinical trial for the treatment of generalized anxiety disorder, as well as is in Phase II clinical trial in patients with post-traumatic stress disorder; BNC375, a small molecule therapeutics for the treatment of cognitive impairment in Alzheimer's disease; BNC101, a monoclonal antibody that targets cancer stem cells; and BNC105, a vascular disrupting agent for the treatment of cancer, as well as disrupts the blood vessels that nourish tumors in cancer treatment. It also offers Multicore, a suite of integrated synthetic methods that gives access to complex drug-like molecules; and ionX, an integrated platform of genomics discoveries and technologies that serves as the foundation for Bionomics' CNS drug discovery and development, as well as contract research services. The company has a collaborative partnership with Merck & Co., Inc. Bionomics Limited was founded in 1998 and is based in Thebarton, Australia.
Medicine Cancer Biopharmaceutical Pharmacology Stem Cells Drug Discovery Treatment Of Cancer Monoclonal Antibodies Alzheimer's Disease Genomics Cancer Treatment Tumors Central Nervous System Disorders Medical Research Contract Research Services Anxiolytics Cognitive Impairment Merck & Co. Post Traumatic Stress Disorder
Is BNOEF a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Recent News
Indicator Value
52 Week High 0.51
52 Week Low 0.0105
Average Volume 14,435
200-Day Moving Average 0.207
50-Day Moving Average 0.0834
20-Day Moving Average 0.0438
10-Day Moving Average 0.0324
Average True Range 0.0125
ADX 23.41
+DI 38.2035
-DI 44.855
Chandelier Exit (Long, 3 ATRs ) 0.0565
Chandelier Exit (Short, 3 ATRs ) 0.048
Upper Bollinger Band 0.085
Lower Bollinger Band 0.0026
Percent B (%b) 0.52
BandWidth 188.127854
MACD Line -0.0129
MACD Signal Line -0.0154
MACD Histogram 0.0024
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 0.0456
Resistance 3 (R3) 0.0456 0.0456 0.0456
Resistance 2 (R2) 0.0456 0.0456 0.0456 0.0456
Resistance 1 (R1) 0.0456 0.0456 0.0456 0.0456 0.0456
Pivot Point 0.0456 0.0456 0.0456 0.0456 0.0456
Support 1 (S1) 0.0456 0.0456 0.0456 0.0456 0.0456
Support 2 (S2) 0.0456 0.0456 0.0456 0.0456
Support 3 (S3) 0.0456 0.0456 0.0456
Support 4 (S4) 0.0456